Kingdon Capital Management, L.L.C. Aurinia Pharmaceuticals Inc. Transaction History

Kingdon Capital Management, L.L.C.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$10.93 - $23.55 $17.3 Million - $37.3 Million	-1,583,208 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$10.0 - $14.52 $1.65 Million - $2.4 Million	-165,000 Reduced 9.44%	1,583,208 $20.5 Million
Q1 2021 May 17, 2021	BUY	$12.3 - $18.73 $984,000 - $1.5 Million	80,000 Added 4.8%	1,748,208 $22.7 Million
Q4 2020 Feb 16, 2021	BUY	$12.94 - $16.05 $776,400 - $963,000	60,000 Added 3.73%	1,668,208 $23.1 Million
Q3 2020 Nov 16, 2020	BUY	$13.19 - $16.66 $3.4 Million - $4.29 Million	257,400 Added 19.06%	1,608,208 $23.7 Million
Q2 2020 Aug 14, 2020	BUY	$14.12 - $18.33 $12.5 Million - $16.3 Million	888,128 Added 191.95%	1,350,808 $22 Million
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $4.75 Million - $8.99 Million	419,011 Added 959.52%	462,680 $6.71 Million
Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $169,435 - $935,389	43,669 New	43,669 $885,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Kingdon Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Kingdon Capital Management, L.L.C. with notifications on news.